Why Indivior’s Sublocade injection is central to long-term opioid treatment

With a once-monthly injection and steady buprenorphine release, Indivior’s Sublocade aims to simplify maintenance therapy for moderate to severe opioid use disorder in the US. We break down how the product works, who it targets, and where it fits in Indivior’s portfolio.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 6:30 PM ET. Details in the imprint.

Sublocade, Indivior’s once-monthly buprenorphine injection for moderate to severe opioid use disorder, sits at the heart of the company’s strategy to provide long-acting treatments that reduce daily pill burden for patients in the United States.

How Sublocade works and who it is for

Sublocade is an extended-release, subcutaneous formulation of buprenorphine designed for adults with moderate to severe opioid use disorder who have already been inducted and clinically stabilized on a transmucosal buprenorphine-containing product for at least seven days. The medication is injected as a liquid into the abdominal subcutaneous tissue, where it forms a solid depot that steadily releases buprenorphine over a one-month period. In the US, it is administered only by healthcare professionals under a restricted distribution program because of risks such as serious injection-site reactions and potential for misuse or diversion.

The prescribing information describes a two-step dosing approach, with an initial recommended dose of 300 mg monthly for the first two months, followed by a maintenance dose that may be either 100 mg or 300 mg monthly depending on patient response and clinical judgment. Clinical trial data included in the label show that Sublocade treatment produced higher proportions of opioid-negative urine samples and greater treatment retention compared with placebo injections when combined with counseling. According to Indivior, the buprenorphine plasma levels achieved with Sublocade are intended to block the rewarding effects of illicit opioids while easing withdrawal and cravings, supporting long-term maintenance in patients engaged in a comprehensive recovery program.

Because the product is based on buprenorphine, a partial opioid agonist with a ceiling effect on respiratory depression, it is positioned as a maintenance therapy rather than an acute detoxification solution. The label emphasizes that treatment should be part of a broader approach including psychosocial support, and it warns that abrupt discontinuation can lead to withdrawal symptoms, requiring careful tapering if therapy is to be stopped. Common adverse reactions listed in the prescribing information include constipation, nausea, injection-site pain and pruritus, headache and insomnia, while serious risks include potential for severe hepatic events and precipitated withdrawal if given to patients not adequately stabilized on buprenorphine beforehand.

From a practical standpoint, Sublocade’s once-monthly dosing is intended to address adherence issues associated with daily sublingual buprenorphine formulations and to reduce the risk of diversion of take-home medication, as confirmed by Indivior’s description of the product’s role in medication-assisted treatment programs for opioid use disorder. For payers and providers, the product is typically reimbursed under medical benefit pathways, and Indivior operates US support programs that assist eligible patients and clinics with access and reimbursement navigation.

Within Indivior’s portfolio, Sublocade complements legacy sublingual buprenorphine products by targeting patients who have stabilized on daily therapy but would benefit from reduced dosing frequency and tighter clinical oversight. Indivior highlights long-acting injectable treatment as a key growth pillar alongside its broader addiction-treatment and mental health pipeline, which also includes investigational assets in areas such as alcohol use disorder and schizophrenia. Shares of Indivior (GB00BYZ0C031) traded on NASDAQ under the ticker INDV at $38.48 at the close on 06/12/2026, according to recent market data.

Sublocade in brief: the hard facts

• Product: Sublocade (buprenorphine extended-release injection)
• Manufacturer: Indivior PLC
• Category: Flagship addiction-treatment medication
• Launch date: First FDA approval in 2017 (US)
• MSRP / Price: Typically reimbursed under medical benefit; pricing varies by payer and setting
• Availability: Prescription-only in the US, administered by healthcare professionals under a restricted distribution program
• Target audience: Adults with moderate to severe opioid use disorder stabilized on transmucosal buprenorphine
• Key differentiator / USP: Once-monthly, long-acting buprenorphine depot designed to reduce daily pill burden and limit diversion risk

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.